This website is now the new JPND's archival platform. This website hosts all of JPND's archived content and resources.
Please continue to visit this site to access publications, videos and reports from JPND's activities.

Dev

Joined: October 9, 2025
Articles: 6278

survey

Putting the brakes on Alzheimer’s disease: Exercise and its effects on cognitive decline, neurogenesis and inflammation in the APP/PS-1 mouse

Putting the brakes on Alzheimer’s disease: Exercise and its effects on cognitive decline, neurogenesis and inflammation in the APP/PS-1 mouse Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

A National Dementia Registry for Ireland: A feasbility analysis

A National Dementia Registry for Ireland: A feasbility analysis Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Taking the Stress out of Dementia Caregiving

Taking the Stress out of Dementia Caregiving Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Botulinum toxin for sialorrhea in people with Parkinson’s disease

Botulinum toxin for sialorrhea in people with Parkinson’s disease Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Novel biomarkers of ALS subphenotypes using advanced imaging and spectral EEG technology

Novel biomarkers of ALS subphenotypes using advanced imaging and spectral EEG technology Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Angiogenin as a therapeutic for the treatment of ALS

Angiogenin as a therapeutic for the treatment of ALS Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Examining the effects of S1P receptor drugs in Alzheimer’s disease

Examining the effects of S1P receptor drugs in Alzheimer’s disease Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Validation of the Profile for Communication Abilities in Dementia (P-CAD)

Validation of the Profile for Communication Abilities in Dementia (P-CAD) Investments < €500k Ireland 2016

Dev
April 20, 2018

survey

Harnessing the anti-inflammatory potential of cannabinoid CB2 receptors for disease modification in Parkinsons disease

Harnessing the anti-inflammatory potential of cannabinoid CB2 receptors for disease modification in Parkinsons disease Investments < €500k Ireland 2016